Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, September 18, 2020
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Thursday, September 17, 2020
Eisai Establishes Pharma Sales Subsidiary in Vietnam
Friday, September 11, 2020
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
Monday, September 7, 2020
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Tuesday, August 25, 2020
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
Friday, July 31, 2020
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
Wednesday, July 22, 2020
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
Monday, July 20, 2020
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
Tuesday, July 14, 2020
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: